Compare FDC LTD. with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. GLENMARK PHARMA FDC LTD./
GLENMARK PHARMA
 
P/E (TTM) x 16.4 9.9 165.3% View Chart
P/BV x 2.5 1.4 174.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FDC LTD.   GLENMARK PHARMA
EQUITY SHARE DATA
    FDC LTD.
Mar-18
GLENMARK PHARMA
Mar-19
FDC LTD./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs319712 44.8%   
Low Rs164484 33.9%   
Sales per share (Unadj.) Rs61.6349.6 17.6%  
Earnings per share (Unadj.) Rs9.932.8 30.3%  
Cash flow per share (Unadj.) Rs12.044.3 27.0%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs73.2198.6 36.8%  
Shares outstanding (eoy) m174.40282.17 61.8%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.91.7 229.2%   
Avg P/E ratio x24.318.2 133.2%  
P/CF ratio (eoy) x20.213.5 149.7%  
Price / Book Value ratio x3.33.0 109.7%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m42,118168,625 25.0%   
No. of employees `0005.512.0 45.9%   
Total wages/salary Rs m2,16720,561 10.5%   
Avg. sales/employee Rs Th1,943.78,196.0 23.7%   
Avg. wages/employee Rs Th391.71,708.1 22.9%   
Avg. net profit/employee Rs Th313.7768.5 40.8%   
INCOME DATA
Net Sales Rs m10,75198,655 10.9%  
Other income Rs m5102,081 24.5%   
Total revenues Rs m11,260100,736 11.2%   
Gross profit Rs m2,26715,858 14.3%  
Depreciation Rs m3513,259 10.8%   
Interest Rs m143,346 0.4%   
Profit before tax Rs m2,41111,335 21.3%   
Minority Interest Rs m-50-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m6713,756 17.9%   
Profit after tax Rs m1,7359,250 18.8%  
Gross profit margin %21.116.1 131.2%  
Effective tax rate %27.833.1 84.0%   
Net profit margin %16.19.4 172.1%  
BALANCE SHEET DATA
Current assets Rs m7,21366,968 10.8%   
Current liabilities Rs m2,10440,211 5.2%   
Net working cap to sales %47.527.1 175.2%  
Current ratio x3.41.7 205.9%  
Inventory Days Days5483 65.4%  
Debtors Days Days2881 34.1%  
Net fixed assets Rs m6,86533,322 20.6%   
Share capital Rs m175282 62.1%   
"Free" reserves Rs m12,58655,770 22.6%   
Net worth Rs m12,76156,052 22.8%   
Long term debt Rs m635,738 0.0%   
Total assets Rs m15,041132,888 11.3%  
Interest coverage x173.24.4 3,948.0%   
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x0.70.7 96.3%   
Return on assets %11.69.5 122.7%  
Return on equity %13.616.5 82.4%  
Return on capital %19.017.8 106.4%  
Exports to sales %12.30-   
Imports to sales %00-   
Exports (fob) Rs m1,327NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,88962,998 3.0%   
Fx outflow Rs m022,859 0.0%   
Net fx Rs m1,88940,140 4.7%   
CASH FLOW
From Operations Rs m1,49813,242 11.3%  
From Investments Rs m201-6,990 -2.9%  
From Financial Activity Rs m-1,694-7,387 22.9%  
Net Cashflow Rs m10-2,971 -0.3%  

Share Holding

Indian Promoters % 68.9 48.3 142.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 6.9 68.1%  
FIIs % 7.5 34.4 21.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 10.5 181.0%  
Shareholders   23,730 56,727 41.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare FDC LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

FDC LTD. Announces Quarterly Results (2QFY20); Net Profit Up 45.4% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Nov 14, 2019 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FDC LTD. 8-QTR ANALYSIS

COMPARE FDC LTD. WITH

MARKET STATS